Repricing unfolds across Europe as trade pressures ease

Europe stocks

In Asia, Japanese equities surged decisively as export‑heavy sectors regained confidence following a reported trade framework with the United States that reduces auto tariffs to 15 %, down from a previously threatened 25 %. The Nikkei posted gains of approximately 3.7 %, propelled by automakers whose policy relief reshapes near‑term cost structures and trade outlooks. This rally extended regionally, capturing advances in Australia, Korea and broader Asia‑Pacific indices, as the market embraced reduced trade friction.

In Europe, the STOXX 600 index rallied to reach four‑month highs, with major bourses such as Germany’s DAX and France’s CAC 40 posting firm gains, while the UK’s FTSE 100 advanced more modestly. The trade agreement, disclosed at the end of July, institutes a 15 % tariff on most EU exports to the US, replacing the previously threatened 30 % level and providing much needed regulatory certainty ahead of a key August deadline. In return, the EU committed to significant investment and energy purchases, cumulatively valued in the hundreds of billions of dollars.

This resolve from investors to re‑embrace risk reflects renewed stability. Auto manufacturers across the continent rose sharply after months of suspended guidance amid tariff uncertainty. Semiconductor and healthcare names also advanced, with strong interest in firms tied to core export verticals. Luxury goods posted steadier gains, buoyed by speculation around renewed deal activity and balance sheet restructuring.

However, mixed sentiment emerged around the deal’s structure. While the agreement defused the immediate threat of a full‑blown trade standoff, some European leaders described the accord as imbalanced. The EU faces pressure to justify significant concessions, particularly in sectors still exposed to elevated costs. Although the headline tariff was reduced from the initial threat, average rates have still risen materially from pre‑2025 levels, with potential inflationary effects on export‑oriented economies.

Looking ahead, the deal is expected to support modest earnings recovery, with forecasted second‑quarter growth edging into positive territory after earlier expectations of contraction. Revenue, however, may still lag, with projected declines pointing to persistent demand headwinds and margin compression. Several companies have already flagged significant one‑off tariff costs that will weigh on full‑year results, with multi‑billion euro adjustments anticipated.

Share on:
Find more news, interviews, share price & company profile here for:

    Fidelity Emerging Markets Ltd outperforms index buoyed by stocks in Brazil, Taiwan and China

    Fidelity Emerging Markets has published its monthly factsheet for August 2025. The Trust reported positive returns, outperforming its benchmark, with stock selection in Brazil, Taiwan and China adding value.

    Fidelity Special Values strong performance reinforces attractiveness of UK equities  

    Fidelity Special Values sees strong 12-month gains as UK equities quietly reward contrarian investors amid persistent capital outflows.

    Fidelity European Trust rises in August, reporting 16.4% returns in 2025

    Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy.

    Real Estate Credit Investments extends share buybacks up to £10 million

    Real Estate Credit Investments has extended its share buyback programme to 31 March 2026 with a limit of up to £10 million. Since the launch of its first programme in 2023, the Company has repurchased over 7.6 million shares for £9.4 million.

    Cizzle Biotechnology US Rollout Begins as Lung Cancer Test Moves from Lab to Clinic (Video)

    Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand.

      Search

      Search